Integrated Medical Sensors Inc.

Integrated Medical Sensors Inc., a minority-owned, small disadvantaged business based in Irvine, California, is a grant-recipient developer of miniaturized, wireless electrochemical biosensing platforms for continuous biomarker monitoring, working as a prime recipient with the National Institutes of Health and the National Science Foundation on federal research grants focused on glucose and multi-analyte monitoring device innovation.

Integrated Medical Sensors operates as a for-profit corporation, self-certified as a small disadvantaged business and Subcontinent Asian American owned, competing exclusively in federal grant programs rather than in contract vehicles. The vendor's grant portfolio centers on biomedical device research and development, specifically the design and human validation of ultra-miniaturized continuous glucose monitoring (CGM) systems using complementary metal-oxide-semiconductor (CMOS) application-specific integrated circuit (ASIC) technology. The company's core technology achieves extreme miniaturization—systems smaller than half a sesame seed—with on-chip multi-sensor integration, improved signal-to-noise ratio for enhanced hypoglycemia detection, and on-chip temperature calibration. Manufacturing methods scale production lot sizes by over 1000 times compared to current commercial CGM systems, with the stated goal of reducing costs and improving affordability for diabetes patients.

Recent prime grant work includes a $922,875 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Project Grant awarded August 25, 2026, running through July 31, 2028, to develop GlucoSoft, a flexible band-aid-format continuous glucose monitoring transmitter using scalable semiconductor and flexible hybrid electronics manufacturing. An earlier $275,275 NIDDK Project Grant (September 17, 2025, through November 30, 2026) addressed the same GlucoSoft platform optimization. A $256,000 National Science Foundation SBIR Phase I award (CFDA 47.084, completed May 31, 2023) supported development of a multi-analyte microsensor platform for continuous wireless monitoring in sub-cubic-millimeter form factors. Integrated Medical Sensors also received NIDDK grants in 2024 and 2023 for optimizing manufacturing frameworks toward FDA IDE approval and developing multi-analyte sensing platforms capable of glucose, ketone, lactate, and temperature monitoring. All performance occurs in Irvine, California.

Customer concentration is narrow and grant-focused: the National Institute of Diabetes and Digestive and Kidney Diseases accounts for 10 of 13 total awards, with the National Science Foundation placing 2 awards and the Department of the Air Force Materiel Command Research Laboratory placing 1 award. Total dollars obligated across all awards reach $7.4 million, with 92 percent as prime awards and 8 percent as sub awards. Three awards face ultimate completion within the next twenty-four months, representing potential recompete opportunity. The vendor holds one federal grant sub-award with Semi (July 27, 2026) addressing multi-analyte, multi-modal CMOS microsensor platform development. Integrated Medical Sensors has no presence on federal contract vehicles, IDIQs, GWACs, or BPAs; its entire federal footprint consists of NIH and NSF research grants supporting device innovation, pre-clinical and clinical feasibility studies, algorithm optimization, and manufacturing scale-up work aimed at commercialization of continuous metabolic monitoring systems for diabetes management.